Вакцины против атеросклероза: настоящее и будущее
Аннотация
Обобщены экспериментальные данные последних лет о применении иммуномодулирующих подходов в лечении атеросклероза. Кратко рассмотрены данные о белках-мишенях антиатерогенных вакцин. Оральное или интраназальное введение белка теплового шока (HSP) и других инфекционных агентов приводит к торможению развития атеросклероза и ассоциируется с изменением баланса про- и антивоспалительных цитокинов и снижением уровня антител к HSP. Значительное снижение развития атеросклеротических бляшек вызывает иммунизация животных окисленными липопротеинами низкой плотности или пептидами модифицированного и нативного апопротеина В. Вакцина против белка, переносящего эфиры холестерина, препятствует развитию дислипопротеинемии и атеросклероза у кроликов и трансгенных мышей. Обсуждаются данные об антиатерогенном действии вакцин к цитокинам, факторам ангиогенеза и антител против CD 40 и 99. Сделано заключение, что создание комбинированной вакцины против атеросклероза является новым перспективным подходом лечения сердечно-сосудистых заболеваний.
Об авторе
М. И. Душкин
РАМН
Россия
Россия
Михаил Иванович Душкин, д-р мед. наук, проф., зав. лабораторией
СО РАМН
Учреждение Российской академии медицинских наук Научно-исследовательский институт терапии
лаборатория молекулярно-клеточных механизмов терапевтических заболеваний
630089
ул. Б. Богаткова, 175/1
Новосибирск
Список литературы
1. Maron R., Sukhova G., Faria A. M. et al. Mucosal administration of heat shock protein-65 decreases atherosclerosis and inflammation in aortic arch of low-density lipoprotein receptor-deficient mice // Circulation. 2002. Vol. 106. P. 1599–1601.
2. Frostegard J. Autoimmunity, oxidized LDL and cardiovascular disease // Autoimmun Rev. 2002. Vol. 1. P. 233–237.
3. Walton K. A., Cole A. L., Yeh M. et al. Specific phospholipid oxidation products inhibit ligand activation of toll-like receptors 4 and 2 // Arterioscler. Tromb. Vasc. Biol. 2003. Vol. 23. P. 1197–1203.
4. Murray C. J., Lopes A. D. Alternative projections of mortality and disability by cause 1990-2020 global bur den of disease study // Lancet. 1997. Vol. 346. P. 1498–1504.
5. Skalen K., Gustafsson M., Rydberg E. K. et al. Subendothelial retention of atherogenic lipoproteins in early atherosclerosis // Nature. 2002. Vol. 417. P. 750–754.
6. Sloan-Lancaster J., Allen P. M. Altered peptide ligandinduced partial T cell activation: molecular mechanisms and role in T cell biology // Annu Rev. Immunol. 1996. Vol. 14. P. 1–27.
7. Wick G., Xu Q. Atherosclerosis – an autoimmune disease // Exp. Gerantol. 1999. Vol. 34. P. 559–566.
8. Williams K. J., Tabas I. The response-to-retention hypothesis of atherogenesis reinforced // Curr. Opin. Lipidol. 1998. Vol. 9. P. 471–474.
9. Hu X., Dietz J. D., Xia C. et al. Torcetrapib induces aldosterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein inhibition // Endocrinology. 2009. Vol. 150. P. 2211–2219.
10. Edfeldt K., Swedenborg J., Hannsson G. K., Yan Z. Q. Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation // Circulation. 2002. Vol. 105. P. 1158–1161.
11. van Es T., van Puijvelde G. H., Michon I. N. et al. IL-15 aggravates atherosclerotic lesion development in LDL receptor deficient mice // Vaccine. 2011. Vol. 29. P. 976–983.
12. Xu X. H., Shah P. K., Faure E. et al. Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDl // Circulation. 2001. Vol. 104. P. 3103–3108.
13. Taylor-Robinson D., Thomas B. J. Chlamidia pneumoniae in arteries: the fact, there interpretation, and future studies // J. Clin. Pathol. 1998. Vol. 51. P. 793–797.
14. Perschinka H., Mayr M., Milloning G. et al. Crossreactive B-cell epitopes of microbial and human heat shock protein 60/65 in atherosclerosis // Arterioscler. Tromb. Vasc. Biol. 2003. Vol. 23. P. 1060–1065.
15. Afek A., George J., Gilburg B. et al. Immunization of LDL receptor deficient mice with heat shok protein 65promotes early atherosclerosis // J. Autoimmun. 2000. Vol. 14. P. 115–121.
16. Xu Q., Dietrich H., Steiner H. J. et al. Induc tion of atherosclerosis in normocholesterolemic rabbits by immunization with heat shock protein 65 // Arte rioscler. Tromb. Vasc. Biol. 1992. Vol. 12. P. 789–799.
17. Lamb D. J., Ferns G. A. The magnitude of the immune to heat shock protein-65 following BCG immunization is associated with the extent of experimental athe rosclerosis // Atherosclerosis. 2002. Vol. 165. P. 231–240.
18. Shibata Y., Ohata H., Yamashita M. et al. Immunologic response enhances atherosclerosis-type 1 helper T cell (Th1) totype 2 helper T cee (Th2) shift and clacificated atherosclerosis in BCG-treated apolipoprotein E-knockaut mice// Trans. Res. 2007. Vol. 149. P. 62–69.
19. Frostegard J., Ulfgren A. K., Niberg P. et al. Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophagestimulating cytokines // Atherosclerosis. Vol. 145. P. 33–43.
20. Zhou X., Caligiuri G., Hamsten A. et al. LDL immunization induces T-cell-dependent antibody formation and protection against athero sclerosis // Arterioscler. Tromb. Vasc. Biol. 2001. Vol. 21. P. 108–114.
21. Zhou X., Nicoletti A., Elhage R., Hansson G. K. Transfer of CD4(+) T cells aggravates atherosclerosis in immunodeficient apolipoprotein knockout mice // Circulation. 2000. Vol. 102. P. 2919–2922.
22. Mallat Z., Gojova A., Brun V. et al. Induction of regulatory T cell tipe 1 response reduces the development of atherosclerosis in apolipoprotein E-knockaut mice // Circulation. 2003. Vol. 108. P. 455–458.
23. Robertson A. K., Rudling M., Zhou X. et al. Distruption of TGF-beta signaling in T cells accelerates atherosclerosis // J. Clin. Invest. 2003. Vol. 112. P. 1342–1350.
24. Tupin E., Nicoltti A., Ethage R. et al. Cd1d-dependent activation of NKT cells aggravates atherosclerosis // J. Exp. Med. 2004. Vol. 199. P. 417–422.
25. Caligiuri G., Nicoletti A., Poirier B., Hansson G. K. Protective immunity against atherosclerosis carried by B cells of hypercholesterolic mice // J. Clin. Invest. 2002. Vol. 109. P. 745–753.
26. Makheja A. N., Bloom S., Muesing R. et al. Anti-inflammatory drugs in experimental atherosclerosis. 7. Spontaneous atherosclerosis in WHHL rabbits and inhibition by cortisone acetate // Atherosclerosis. 1989. Vol. 76. P. 115–161.
27. Andersen H. O., Holm P., Stenger S. et al. Dose-dependent suppression of transplantant atherosclerosis in aorta-allografted, cholesterol-clamped rabbits. Suppression not eliminated by the cholesterol-raising effect of cyclosporine // Arterioscler. Tromb. Vasc. Biol. 1997. Vol. 17. P. 2515–2523.
28. Gordon S. Pattern recognition receptors: doubling up for the innate immune respose // Cell. 2002. Vol. 111. P. 927–930.
29. Душкин М. И. Влияние оксистеролов и аторвастатина на ЛПС-индуцированную секрецию фактора некроза опухоли и интерлейкина-10 макрофагами мыши / М. И. Душкин [и др.] // Бюл. экперим. биол. мед. – 2006. – Т. 141, № 2. – С. 194–197.
30. Перминова О. М. Влияние цитокинов на метаболизм холестерина в макрофагах / О. М. Перминова, Н. Н. Вольский, М. И. Душкин. – Система цитокинов: теоретические и клинические аспекты / под ред. В. А. Козлова, С. В. Сенникова. – Новосибирск, 2004. – С. 109–121.
31. Душкин М. И. Интеграция сигнальных путей регуляции липидного обмена и воспалительного ответа / М. И. Душкин, Е. Н. Кудимова, Я. Ш. Шварц // Цитокины и воспаление. – 2007. – № 2. – С. 12–18.
32. Rittershaus C. W., Miller D. P., Thomas L. J. et al. Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis // Arterioscler. Tromb. Vasc. Biol. 2000. Vol. 20. P. 2106–2112.
33. Ansell B., Hobbs F. D. The potential for CETP inhibition to reduce cardiovascular disease risk // Curr. Med. Res. Opin. 2006. Vol. 22. P. 2467–2478.
34. Gaofu Q., Dan M., Jie W. et al. Long-lasting specific antibodies against CETP induced by subcutaneous and mucosal administration of a 26-amino acid CETP epitope carried by shok protein 65 kDa in absence of adjuvants // Vac cine. 2004. Vol. 22. P. 3187–3194.
35. Gaofu Q., Jun L., Xin Y. et al. Vaccinating rabbits with a cholesteryl es ter protein (CETP) b-cell epitope carried by HSP-65 for inducting anti-CETP antibodies and reducing aortic lesions in vivo // J. Cardiovasc. Pharmacol. 2005. Vol. 45. P. 591–598.
36. Mao D., Kai G., Gaofu Q. et al. Intramuscular immunization with DNA vaccine encoding a 26-amino acid CETP epitope displayed by HBc protein and containing CpG DNA inhibits atherosclerosis in a rabbit model of atherosclerosis // Vaccine. 2006. Vol. 24. P. 4942–4950.
37. Qi G., Li J., Wang S. et al. A chimeric peptide of intestinal trefoil factor containing cholesteryl ester transfer protein B cell epitope significantly inhibits atherosclerosis in rabbits after oral administration // Peptides. 2010 (in press).
38. Chyu K. Y., Nilsson J., Shah P. K. Active and passive immunization for atherosclerosis // Curr. Opin. Mol. Ther. 2007. Vol. 9. P. 176–182.
39. Palinski W., Miller E., Witztum J. L. Immunization of LDL receptor-deficient rabbits with homologous malon-dialdehyde-modified LDL reduces atherogenesis // Proc. Natl. Acad. Sci. USA. 1995. Vol. 92. P. 821–825.
40. Ameli S., Hultgardh-Nilsson A., Regnstrom J. et al. Effect of immunization with homologous LDL and oxidized LDL on early atherosclerosis in hyper cho leste rolemic rab bits // Arterioscler. Thromb. Vasc. Biol. 1996. Vol. 16. P. 1074–1079.
41. Freigang S., Horkko S., Miller E. et al. Immunization of LDL receptor-dificient mice with homologous malondialdehyde-modified and na tive LDL reduces progres sion of atherosclerosis by me chanism sotherthan induction of high titers of anti bodies to oxidative epi topes // Arterioscler. Tromb. Vasc. Biol. 1998. Vol. 18. P. 1972–1982.
42. Gorge J., Afeck A., Gilburd B. et al. Hyperimmunization of apo-E-deficient mice with homologous MDA LDL suppresses early atherogenesis // Atherosclerosis. 1998. Vol. 138. P. 147–152.
43. Palinski W., Rosenfeld M. E., Yla-Herttuala S. et al. Low density lipo protein undergoes modification in vivo // Proc. Natl. Acad. Sci. USA. 1989. Vol. 86. P. 1372–1376.
44. Salonen J. T., Yla-Hertuala S., Yamamoto R. et al. Autoantibody against oxidized LDL and progression of ca rotid atherosclerosis // Lancet. 1992. Vol. 339. P. 883–887.
45. Pedersen T. X., Binder C. J., Fredrikson G. N. et al. The pro-inflammatory effect of uraemia overrules the antiatherogenic potential of im mu nization with oxidized LDL in apoE-/- mice // Nephrol. Dial. Transplant. 2010. Vol. 8. P. 2486–2491.
46. Fredrison G. N., Hedblad B., Berglund G. et al. Identification of immune responses against aldechyde-modified peptide sequences in apoB associated with cardiovascular disease // Arterioscler. Thromb. Vasc. Biol. 2003. Vol. 23. P. 872–878.
47. Fredrikson G. N., Soderberg I., Lindholm M. et al. Inhibition of athe rosclerosis in apoE-null mice by immunization with apoB-100 peptide sequences // Ibid. P. 879–884.
48. Schipu A., Bengtsson J., Soderberg I. et al. Recombinant human antibodies against aldechyde-modified apoB-100 peptide sequences inhibit atherosclerosis // Circulation. 2004. Vol. 110. P. 2047–2052.
49. Fredrikson G. N., Björkbacka H., Söderberg I. et al. Treatment with apo B peptide vac cines inhibits atherosclerosis in human apo B-100 transgenic mice without inducing an increase in pep tide-specific antibodies // J. Intern. Med. 2008. Vol. 264. P. 563–570.
50. Wigren M., Kolbus D., Dunér P. et al. Evidence for a role of regulatory T cells in mediating the athe roprotective effect of apolipoprotein B peptide vaccine // J. Intern. Med. 2010. Vol. 266. P. 1365–1373.
51. Binder C. J., Horkko S., Dewan A. et al. Pneumococcal vaccination decreases atherosclerotic lesion formation:molecular mimicry between Streptococcus pneumoniae and oxidized LDL // Nat. Med. 2003. Vol. 9. P. 736–743.
52. Nguyen J. T., Myers N., Palaia J. et al. Humoral responses to oxidized low-density lipoprotein and related bacterial anti gens after pneumococcal vaccine // Transl. Res. 2007. Vol. 150. P. 172–179.
53. Hauer A. D, Uyttenhove C., de Vos P. et al. Blokade of interleukin-12 function by protein vaccination attenuates atherosclerosis // Circulation. 2005. Vol. 112. P. 1054–1062.
54. Hauer A.D., van Puijvelde G.H., Peterse N. Vaccination against VEGFR 2 atte nuates initiation and progression of atherosclerosis // Arterioscler. Thromb. Vasc. Biol. 2007. Vol. 27. P. 2050–2057.
55. Petrovan R. J., Kaplan C. D., Reisfeld R. A., Curtiss L. K. DNA vaccination against VEGF receptor 2 reduces atherosclerosis in LDL receptor-deficient mice // Arterioscler. Thromb. Vasc. Biol. 2007. Vol. 27. P. 993–995.
56. van Wanrooij E. J., de Vos P., Bixel M. G. et al. Vaccination against CD99 inhibits atherogenesis in low-density lipoprotein receptor-deficient mice // Car diovasc. Res. 2008. Vol. 78. P. 590–596.
57. Hauer A. D., Habets K. L., van Wanrooij E. J. et al. Vaccination against TIE2 reduces atherosclerosis // Atherosclerosis. 2009. Vol. 204. P. 365–371.
58. Chen Y., Inobe J., Kuchroo V. K. et al. Oral tolerance in myelin basic protein T-cell receptor transgenic mice: suppression of autoimmune encephalomyelitis and dose-dependent induction of regulatory cells // Proc. Natl. Acad. Sci. USA. 1996. Vol. 93. P. 388–391.
59. Faunce D. E., Terajewicz A., Stein-Streilein J. Cutting edge: in vitro-generated tolerogenic APC induce CD8+ T regulatory cells that can suppress oncoing experimental autoimmune encephalomyelitis // J. Immunol. 2004. Vol. 172. P. 1991–1995.
60. Harats D., Yacov N., Gilburg B. et al. Oral tolerance with heat shock protein 65 attenuates My cobacterium tuberculosis-induced and high-fad-diet-driven atherosclerosis lesions // J. Am. Coll. Cardiol. 2002. Vol. 40. P. 1333–1338.
61. Pockley A. G., Georgiades A., Thulin T. et al. Serum heat shock protein 70 levels pre dict the development of atherosclerosis in subjects with established hypertension // Hypertension. 2003. Vol. 42. P. 235–238.
62. van Puijvelde G. H. M., Hauer A. D., de Vos P. Induction of oral tolerance to oxidized low-density lipoprotein ameliorates atherosclerosis // Circulation. 2006. Vol. 114. P. 1968–1976.
63. Wigren M., Bengtsson D., Duner P. Atheroprotective effects of alum are associated with capture of oxidized LDL antigens and activation of regulatory T cells // Circulation Research. 2009. Vol. 104. P. e62–e70.
64. Lamb D. J., Ferns G. A. The magnitude of the immune response to heat shock protein-65 following BCG immunization is associated with the extent of experimental atherosclerosis // Atherosclerosis. 2002. Vol. 165. P. 231–240.
65. Jan M., Meng S., Chen N. C., Mai J., Wang H., Yang X. F. Inflammatory and autoimmune reactions in athe rosclerosis and vaccine design informatics // J. Biomed. Biotechnol. 2010. 459798. 16 p. Review
Рецензия
Для цитирования:
Душкин М.И. Вакцины против атеросклероза: настоящее и будущее. Атеросклероз. 2011;7(1):35-44.
For citation:
Dushkin M.I. Atherosclerosis vaccine: the present and the future. Ateroscleroz. 2011;7(1):35-44. (In Russ.)
Просмотров:
652
Послать статью по эл. почте 